Direct Switching from Irbesartan/Amlodipine to Telmisartan/HCTZ

Rationale for Direct Switching

• The American Heart Association recommends that telmisartan 80mg can be directly switched from irbesartan 150mg without a washout period, as it provides equivalent or superior blood pressure control 1, 2
• The European Society of Cardiology states that both medications are angiotensin II receptor antagonists with similar mechanisms of action, making direct switching safe without a washout period 3, 4

Critical Monitoring Requirements

• The American College of Cardiology recommends checking serum potassium and creatinine within 1-2 weeks after switching to detect hyperkalemia or hypokalemia, with a strength of evidence level of B 1, 2
• Monitoring for hyponatremia, hyperuricemia, and glucose intolerance is necessary, as these are metabolic adverse effects associated with HCTZ, according to the American Diabetes Association 1

Important Caveats and Contraindications

• The FDA recommends avoiding telmisartan in pregnancy due to teratogenicity, and verifying pregnancy status in women of childbearing potential before switching 2, 3
• The European Society of Cardiology advises against combining telmisartan with ACE inhibitors or direct renin inhibitors due to increased risk of hyperkalemia, hypotension, and renal dysfunction, with a strength of evidence level of A 3

Practical Implementation

• The American Heart Association recommends starting telmisartan 80mg/HCTZ 12.5mg once daily, with a follow-up schedule to check serum potassium, creatinine, sodium, and glucose at week 1-2, and reassessing blood pressure and symptoms at week 2-4 1, 2, 3